Detalhe da pesquisa
1.
Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials.
Blood
; 142(3): 235-243, 2023 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37140031
2.
Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials.
Cytotherapy
; 24(7): 742-749, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35219582
3.
FDA approval summary: Crizotinib for pediatric and young adult patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Pediatr Blood Cancer
; 69(8): e29602, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35561013
4.
FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Oncologist
; 26(10): 879-886, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34132444
5.
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Oncologist
; 26(10): e1786-e1799, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34196068
6.
Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant
; 26(10): e247-e255, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32589921
7.
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.
Biol Blood Marrow Transplant
; 25(3): e89-e97, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30408566
8.
The saga of PI3K inhibitors in haematological malignancies: survival is the ultimate safety endpoint.
Lancet Oncol
; 23(5): 563-566, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35429996
9.
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
Oncologist
; 22(11): 1347-1353, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28904172
10.
Immunotherapy Combinations in Multiple Myeloma - Known Unknowns.
N Engl J Med
; 379(19): 1791-1795, 2018 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30403935
11.
Proteasome inhibitor-associated thrombotic microangiopathy: A review of cases reported to the FDA adverse event reporting system and published in the literature.
Am J Hematol
; 95(9): E218-E222, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32291777
12.
Repair of impaired pulmonary function is possible in very-long-term allogeneic stem cell transplantation survivors.
Biol Blood Marrow Transplant
; 20(2): 209-13, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24188917
13.
Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation.
Biol Blood Marrow Transplant
; 20(7): 969-78, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24657447
14.
FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.
Clin Cancer Res
; 30(1): 17-22, 2024 01 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37624619
15.
A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma.
Clin Cancer Res
; 2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38416426
16.
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.
Blood Cancer Discov
; 5(3): 146-152, 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38441243
17.
FDA Analysis of Ineligibility for Acute Myeloid Leukemia Clinical Trials by Race and Ethnicity.
Clin Lymphoma Myeloma Leuk
; 23(6): 463-470.e1, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37076368
18.
The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990-2018.
Cancer Epidemiol Biomarkers Prev
; 32(6): 744-747, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37012203
19.
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective.
Clin Cancer Res
; 29(15): 2748-2752, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36892497
20.
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021.
JAMA Oncol
; 9(2): 266-272, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36580315